Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | hexokinase | 0.0635 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0635 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0635 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0635 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0635 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0635 | 1 | 0.5 |
Onchocerca volvulus | 0.0635 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.0635 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.0635 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.0635 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0635 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0635 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0635 | 1 | 1 |
Onchocerca volvulus | 0.0635 | 1 | 1 | |
Entamoeba histolytica | hexokinase 2 | 0.0635 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0433 | 0.1468 | 0.1468 |
Loa Loa (eye worm) | hexokinase | 0.0635 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0635 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0635 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.0635 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0635 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0635 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0635 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0635 | 1 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0635 | 1 | 0.5 |
Onchocerca volvulus | 0.0635 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.0635 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0635 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0635 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0635 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.